AutoICD API

74041-5

Laboratory

BCR-ABL1 p210 Major Molecular Response (MMR) [Presence] in Blood or Tissue by Molecular genetics method --post treatment

Definition

Patient's with CML and undergoing tyrosine kinase inhibitor (TKI) therapy may be monitored to assess their treatment response (reduction in BCR-ABL1 transcripts) to therapy. A major molecular response (MMR) occurs when the ratio of BCR-ABL1 transcripts to control gene is less than or equal to 0.1% according to the International Scale (IS), a consensus standardized measurement scale intended to allow direct comparison of BCR-ABL1 major breakpoint (b2a2, b3a2) RNA levels in any laboratory adopting its use. Studies have demonstrated that achieving MMR within 18 months following TKI therapy is associated with a minimal risk of progression at 84 months (NCCN Guidelines CML, 2013).

LOINC 6-Axis Classification

Component

t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript.reduction to 0.1%^post treatment

Property

PrThr

Time Aspect

Pt

System

Bld/Tiss

Scale Type

Ord

Method Type

Molgen

Details

Class

MOLPATH

Order/Observation

Both

Short Name

t(ABL1,BCR)p210/cntrl.0.1% p Tx Bld/T Ql

Display Name

t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript.reduction to 0.1% post treatment Molgen Ql (Bld/Tiss)

Related Names

ABLAfterALLbcr/ablBCR1bcr-abl1BloodBreakpoint cluster regionChronic myeloid leukemiaCMLD22S11D22S662DNAe13a2e14a2gene fusiongene translocationGeneticsHematologyHemeHeredityHeritableInheritedJTK7major breakpointsMbrMcrminor breakpointsMolecular geneticsMolecular pathologyMOLPATHOrdinalp Txp150p210PCRPh chromosomePhiladelphia chromosomePHLPoint in timePRPSTQLQualQualitativeRandomRNAScreenT primet(9,22)(ABL1,BCR) gene translocationt(9,22)(ABL1,BCR) p210 gene translocationt(9,22)(ABL1,BCR) Translocationt(9,22)(q34,q11)t(9,22)(q34.1,q11)t(922)(ABL1,BCR)t(ABL1,BCR)b2a2t(ABL1,BCR)p210TissueTissue, unspecifiedtranslocationTxv-abl Abelson murine leukemia viral oncogene homolog 1WBWhole bloodWhole blood or Tissue

Frequently Asked Questions

What is LOINC code 74041-5?

LOINC code 74041-5 identifies "BCR-ABL1 p210 Major Molecular Response (MMR) [Presence] in Blood or Tissue by Molecular genetics method --post treatment". Patient's with CML and undergoing tyrosine kinase inhibitor (TKI) therapy may be monitored to assess their treatment response (reduction in BCR-ABL1 transcripts) to therapy. A major molecular response (MMR) occurs when the ratio of BCR-ABL1 transcripts to control gene is less than or equal to 0.1% according to the International Scale (IS), a consensus standardized measurement scale intended to allow direct comparison of BCR-ABL1 major breakpoint (b2a2, b3a2) RNA levels in any laboratory adopting its use. Studies have demonstrated that achieving MMR within 18 months following TKI therapy is associated with a minimal risk of progression at 84 months (NCCN Guidelines CML, 2013).

What does 74041-5 measure?

This code measures t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript.reduction to 0.1%^post treatment in Bld/Tiss. It belongs to the MOLPATH class in the LOINC classification.

What is LOINC?

LOINC (Logical Observation Identifiers Names and Codes) is a universal standard for identifying laboratory and clinical observations. It is maintained by the Regenstrief Institute and used worldwide for health data exchange.